How Bayer Secured The Top-Spot In China: An Interview With Liam Condon
This article was originally published in PharmAsia News
Executive Summary
With China set to become the third largest pharmaceutical market in the world by 2011, and the second largest OTC market next year, Bayer Schering Pharma AG is well-positioned to benefit. Larger in China than most of its Western counterparts, with over $750 million in 2008 sales, accounting for an unusually high 4.8% of global health care revenues, Bayer has understood and adapted to the fundamental differences between the Chinese market and those closer to home